FES-PET for Metastatic Breast Cancer

The PI of this project was:

This project was funded by: ECOG/ACRIN 142 Clinical Trial

The term of this project was: February 2016 to February 2021

The number of subjects scanned during this project was: 99

This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may “light up” where cancer is in the body. Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment.

NCT02398773 (clinicaltrials.gov)